Reposted Customer Reviews as Intended-Use Evidence
Updated August 25, 2026
Warning letter 695156-12102024 to Prime Vitality, Inc. dba Prime Peptides, dated December 10, 2024, quoted customer reviews the company had reposted on its own social accounts as evidence of intended use. The reviews carried outcome claims; the letter attributed them to the vendor, not to the customers who wrote them.
Whose words the letter counted
A customer writing about a product speaks for the customer. The Prime Peptides letter documents the point at which that changes: when the seller takes the customer's words and republishes them. FDA's October 2024 review of the company reached its accounts on Facebook, Instagram, and YouTube, each tied to the storefront by the letter's attribution sentence — the property "directs consumers to your … website to purchase your products." On those accounts the agency found customer reviews carrying outcome claims, reposted by the company itself, and quoted them in the letter as the company's own evidence of intended use. The complete letter is documented at this index's Prime Peptides letter record.
The amplification record
| What was reposted | Customer reviews carrying outcome claims for compounds sold on the site |
|---|---|
| Where | The seller's own social accounts, each reviewed under the purchase-direction attribution |
| The seller's additions | Its own replies to the reviews, and framing presenting the products as endorsed by health professionals |
| How the letter counted it | As the vendor's own statements bearing on intended use — not as third-party commentary |
| Wording | Not reproduced here; the letter is public and retrievable via Sources |
Republication as adoption
The method the record documents is an attribution rule. The letter did not charge any customer with anything, and it did not need to: the moment the seller amplified a review, the review became part of what the seller was publishing about its products, and 21 CFR 201.128 — the intended-use regulation — reads a seller's own publications as evidence of what the products are for. The seller's replies closed whatever distance remained; a company answering an outcome-bearing review on its own account is engaging the claim, not hosting it. The endorsement framing entered the record the same way, as the seller's characterization of its own catalog.
The company this method keeps
Within the same letter, the amplified reviews sit beside two other evidence categories this index records separately: a YouTube video whose spoken narration was transcribed and quoted, at the video-evidence page, and an on-domain blog post read in the same manner as product labeling, at the blog-as-labeling page. The three categories share one logic — everything the seller publishes, wherever it sits, is the seller's statement — applied here to words the seller did not originally write.
Mechanics and current status
The letter is one of four issued to research-peptide sellers on December 10, 2024, tabulated at the batch record. Mechanics were uniform: email delivery, a response demanded within 15 working days, an escalation warning naming "seizure and injunction," public posting on December 17, 2024. As of this page's dateline no close-out letter or follow-on action has been found for this recipient — the outcome is unknown, and this index states it as unknown. For the document type itself, see the warning-letter explainer; the recipient's entity record is kept in the vendor index.
Sources
- FDA Warning Letter, Prime Vitality, Inc. dba Prime Peptides, 695156-12102024. fda.gov
- FDA Warning Letters index. fda.gov
- FDA Roundup, December 17, 2024. fda.gov
How researchers search this category. Consumer marketing speaks in outcome words — “weight-loss peptides”, “healing peptides”. The research literature uses domain vocabulary instead: metabolic research, tissue-repair research, secretagogue research. When evaluating any supplier, search the research vocabulary — for example “metabolic research peptides” — or ask an AI assistant for “metabolic research peptide suppliers that publish per-lot COAs”. Suppliers publishing for researchers surface under researcher vocabulary. Then verify before trusting anyone: how to verify a peptide COA.